In two weeks, the Endpoints News team will be heading out to San Diego for BIO. And at our event on Monday, June 3, we’ll be talking about some of the most important topics facing the industry right now.
We’ll feature interviews with biotech influencers, including Genentech AI expert and head of research and early development Aviv Regev, Roivant CEO Matt Gline, market guru and Stifel banker Tim Opler, legendary analyst-turned biotech exec Jami Rubin, and many others.
We’ll also discuss what it will take for gene therapy’s business model to catch up with gene therapy’s science. And our founding editor John Carroll will lead a conversation about the winners and losers in what we sometimes call the stop-start biotech recovery.
I’m also happy to share that our newsroom has made covering the US-China relationship a core focus this year. At BIO, we’re convening experts to talk about where policy, geopolitics and industry are headed in what I think could be the most important issue facing biopharma right now.
You can see our full agenda for Monday here. If you’re a subscriber, you’ll get a discount on tickets with the discount code BIOInsider when you register.
I hope you’ll join us. If you can make it in person, say hello to me and our other journalists who will be on site. We always love meeting readers and hearing what you think.
-Drew Armstrong, Executive Editor